(Q35188424)

7 August 2017

1 reference

title

Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability (English)

1 reference

7 August 2017

0 references

Tahir Masud

1

1 reference

7 August 2017

Sandro Giannini

series ordinal

2

1 reference

7 August 2017

publication date

1 April 2003

1 reference

Aging Clinical and Experimental Research

7 August 2017

published in

1 reference

7 August 2017

volume

15

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

89-98

1 reference

Clinical consequences of vertebral fractures

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

The clinical impact of vertebral fractures: quality of life in women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

A model of lifetime osteoporosis impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Hip fractures in the elderly: a world-wide projection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

The worldwide problem of osteoporosis: insights afforded by epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Risk of new vertebral fracture in the year following a fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Risedronate reduces the risk of first vertebral fracture in osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Tiludronate: development as an osteoporosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Intermittent cyclic tiludronate in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Alendronate and naproxen are synergistic for development of gastric ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03324485

21 January 2018

Identifiers

DOI

10.1007/BF03324485

1 reference

7 August 2017

1 reference